The Effectiveness of Nucleoside Analogues in Chronic Hepatitis B Patients Unresponsive to Interferon Therapy: Our Clinical Trials for One Year

AUTHORS

Sukran Kose 1 , * , Melda Turken 2 , Gulsun Cavdar 2 , Gulgun Akkoclu 2

1 Tepecik Research and Training Hospital, Clinic of Clinical Microbiology and Infectious Diseases, Tepecik, [email protected], Turkey

2 Tepecik Research and Training Hospital, Clinic of Clinical Microbiology and Infectious Diseases, Tepecik, Turkey

How to Cite: Kose S, Turken M, Cavdar G, Akkoclu G. The Effectiveness of Nucleoside Analogues in Chronic Hepatitis B Patients Unresponsive to Interferon Therapy: Our Clinical Trials for One Year, Hepat Mon. Online ahead of Print ; 10(4):289-293.

ARTICLE INFORMATION

Hepatitis Monthly: 10 (4); 289-293
Article Type: Research Article
Received: February 2, 2010
Accepted: August 20, 2010

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background and Aims: We aimed to evaluate the effectiveness of nucleoside analogues such as Lamivudine, Adefovir, Entacavir, and Tenofovir in patients with chronic hepatitis B who failed to respond to interferon therapy and relapsed.
Materials and Methods: We followed a total of 73 patients with hepatitis B in the hepatitis outpatient clinic in our hospital. The patients subsequently received nucleoside analogues therapy and their treatment data were evaluated retrospectively. The biochemical and virological response rates were evaluated at 3 and 12 months, and we compared these results with the results of treatment-naive patients.
Results: There were 29 (39.7%) HbeAg-positive and 44 (60.3%) HbeAg-negative patients, and their mean age was 35.8 (±13.4) years. Of these patients, 33, 18, 13 and 9 received Entacavir, Tenofovir, Lamivudine, and Adefovir treatment, respectively. In HbeAg-negative patients, at 3 months the biochemical and virological response (early response) rates were observed to be 91% and 98%), and at 12 months the two rates were 93% and 73%, respectively. In HbeAg-positive patients, the biochemical and virological response rates at 3 months were 83% and 97%, and the rates at 12 months were 90% and 48%, respectively.
Conclusions: In CHB therapy with treatment-resistent patients, nucleoside analogues may be preferable. There are disadvantages to nucleoside analogues, such as a risk of developing resistance during therapy, reduced HBeAg seroconversion compared to interferons, and the therapy's ambiguous duration. In our study, in HbeAg-negative patients who received nucleoside analogues, a lower biochemical response rate was detected in patients with 1 year of Lamivudine therapy compared to other therapies.  For HbeAg-positive patients, the virological response rate was higher in 1 year of Tenofovir therapy than with other therapies.

Keywords

Hepatitis B Virus nucleoside analogues interferon therapy

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: